In ionotropic GABAA receptors, binding of GABA molecules to their binding sites in the extracellular part of the receptor triggers opening of a chloride ion-selective pore. The increased chloride conductance drives the membrane potential towards the reversal potential of the Cl¯ ion which is about –75 mV in neurons, inhibiting the firing of new action potentials. This mechanism is responsible for the sedative effects of GABAA allosteric agonists. In addition, activation of GABA receptors lead to the so-called shunting inhibition, which reduces the excitability of the cell independent of the changes in membrane potential.
There have been numerous reports of excitatory GABAA receptors. According to the excitatory GABA theory, this phenomenon is due to increased intracellular concentration of Cl¯ ions either during development of the nervous system or in certain cell populations. After this period of development, a chloride pump is upregulated and inserted into the cell membrane, pumping Cl− ions into the extracellular space of the tissue. Further openings via GABA binding to the receptor then produce inhibitory responses. Over-excitation of this receptor induces receptor remodeling and the eventual invagination of the GABA receptor. As a result, further GABA binding becomes inhibited and inhibitory postsynaptic potentials are no longer relevant.
However, the excitatory GABA theory has been questioned as potentially being an artefact of experimental conditions, with most data acquired in in-vitro brain slice experiments susceptible to un-physiological milieu such as deficient energy metabolism and neuronal damage. The controversy arose when a number of studies have shown that GABA in neonatal brain slices becomes inhibitory if glucose in perfusate is supplemented with ketone bodies, pyruvate, or lactate, or that the excitatory GABA was an artefact of neuronal damage. Subsequent studies from originators and proponents of the excitatory GABA theory have questioned these results, but the truth remained elusive until the real effects of GABA could be reliably elucidated in intact living brain. Since then, using technology such as in-vivo electrophysiology/imaging and optogenetics, two in-vivo studies have reported the effect of GABA on neonatal brain, and both have shown that GABA is indeed overall inhibitory, with its activation in the developing rodent brain not resulting in network activation, and instead leading to a decrease of activity.
GABA receptors influence neural function by coordinating with glutamatergic processes.
GABAС receptors are exclusively composed of ρ (rho) subunits that are related to GABAA receptor subunits. Although the term "GABAС receptor" is frequently used, GABAС may be viewed as a variant within the GABAA receptor family. Others have argued that the differences between GABAС and GABAA receptors are large enough to justify maintaining the distinction between these two subclasses of GABA receptors. However, since GABAС receptors are closely related in sequence, structure, and function to GABAA receptors and since other GABAA receptors besides those containing ρ subunits appear to exhibit GABAС pharmacology, the Nomenclature Committee of the IUPHAR has recommended that the GABAС term no longer be used and these ρ receptors should be designated as the ρ subfamily of the GABAA receptors (GABAA-ρ).
A slow response to GABA is mediated by GABAB receptors, originally defined on the basis of pharmacological properties.
In studies focused on the control of neurotransmitter release, it was noted that a GABA receptor was responsible for modulating evoked release in a variety of isolated tissue preparations. This ability of GABA to inhibit neurotransmitter release from these preparations was not blocked by bicuculline, was not mimicked by isoguvacine, and was not dependent on Cl¯, all of which are characteristic of the GABAA receptor. The most striking discovery was the finding that baclofen (β-parachlorophenyl GABA), a clinically employed muscle relaxant mimicked, in a stereoselective manner, the effect of GABA.
^Kravitz EA, Kuffler SW, Potter DD (September 1963). "Gamma-aminobutyric acid and other blocking compounds in crustacea. III. Their relative concentrations in separated motor and inhibitory axons". J. Neurophysiol. 26: 739–51. doi:10.1152/jn.1918.104.22.1689. PMID14065325.
^Tomiko SA, Taraskevich PS, Douglas WW (February 1983). "GABA acts directly on cells of pituitary pars intermedia to alter hormone output". Nature. 301 (5902): 706–7. doi:10.1038/301706a0. PMID6828152.
^Lamsa K, Taira T (September 2003). "Use-dependent shift from inhibitory to excitatory GABAA receptor action in SP-O interneurons in the rat hippocampal CA3 area". J. Neurophysiol. 90 (3): 1983–95. doi:10.1152/jn.00060.2003. PMID12750426. S2CID17650510.
^Rheims, Sylvain; Holmgren, Carl D.; Chazal, Genevieve; Mulder, Jan; Harkany, Tibor; Zilberter, Tanya; Zilberter, Yuri (August 2009). "GABA action in immature neocortical neurons directly depends on the availability of ketone bodies". Journal of Neurochemistry. 110 (4): 1330–1338. doi:10.1111/j.1471-4159.2009.06230.x. PMID19558450.
^Holmgren, Carl D.; Mukhtarov, Marat; Malkov, Anton E.; Popova, Irina Y.; Bregestovski, Piotr; Zilberter, Yuri (February 2010). "Energy substrate availability as a determinant of neuronal resting potential, GABA signaling and spontaneous network activity in the neonatal cortex". Journal of Neurochemistry. 112 (4): 900–912. doi:10.1111/j.1471-4159.2009.06506.x. PMID19943846.
^Drew CA, Johnston GA, Weatherby RP (December 1984). "Bicuculline-insensitive GABA receptors: studies on the binding of (-)-baclofen to rat cerebellar membranes". Neurosci. Lett. 52 (3): 317–21. doi:10.1016/0304-3940(84)90181-2. PMID6097844.
^Zhang D, Pan ZH, Awobuluyi M, Lipton SA (March 2001). "Structure and function of GABA(C) receptors: a comparison of native versus recombinant receptors". Trends Pharmacol. Sci. 22 (3): 121–32. doi:10.1016/S0165-6147(00)01625-4. PMID11239575.
^Feigenspan A, Wässle H, Bormann J (January 1993). "Pharmacology of GABA receptor Cl- channels in rat retinal bipolar cells". Nature. 361 (6408): 159–62. doi:10.1038/361159a0. PMID7678450.
^Qian H, Dowling JE (January 1993). "Novel GABA responses from rod-driven retinal horizontal cells". Nature. 361 (6408): 162–4. doi:10.1038/361162a0. PMID8421521.
^Wegelius K, Pasternack M, Hiltunen JO, Rivera C, Kaila K, Saarma M, Reeben M (January 1998). "Distribution of GABA receptor rho subunit transcripts in the rat brain". Eur. J. Neurosci. 10 (1): 350–7. doi:10.1046/j.1460-9568.1998.00023.x. PMID9753143.
^Bowery NG, Bettler B, Froestl W, Gallagher JP, Marshall F, Raiteri M, Bonner TI, Enna SJ (June 2002). "International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function". Pharmacological Reviews. 54 (2): 247–64. doi:10.1124/pr.54.2.247. PMID12037141.
^Bowery NG, Hill DR, Hudson AL, Doble A, Middlemiss DN, Shaw J, Turnbull M (January 1980). "(-)Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor". Nature. 283 (5742): 92–4. doi:10.1038/283092a0. PMID6243177.
^Bein HJ (1972). "Pharmacological differentiations of muscle relaxants". In Birkmayer W (ed.). Spasticity: A Topical Survey. Hans Hubert Bern, Switzerland. pp. 76–89. ISBN3-456-00390-0.
^Keberle H, Faigle JW (1972). "Synthesis and structure-activity relationship of the gamma-aminobutyric acid derivatives". In Birkmayer W (ed.). Spasticity: A Topical Survey. Hans Hubert Bern, Switzerland. pp. 76–89. ISBN3-456-00390-0.
^Hill DR, Bowery NG (March 1981). "3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain". Nature. 290 (5802): 149–52. doi:10.1038/290149a0. PMID6259535.
^Enna SJ (2001). "GABAB receptor signaling pathways". In Möhler H (ed.). Pharmacology of GABA and Glycine Neurotransmission (Handbook of Experimental Pharmacology) (Volume 150). Berlin: Springer. pp. 329–342. ISBN3-540-67616-3.